DHEA in women: what the studies included

Reviewed 20 sourcesPublished by PepVault

Who the DHEA trials enrolled: older women, adrenal insufficiency, IVF poor responders and menopause. Each trial's women, ages, dose and result in one table.

Silver-haired woman in a red wrap top dances barefoot in a bright living room
Last reviewed
Sources
20
Questions
7
Compounds
1

The short answer

DHEA has been tested in four groups of women: women over 60 with low levels, women whose adrenal glands have failed, women aged 18 to 42 who respond poorly to IVF, and women aged 40 to 80 with painful sex after menopause. Oral DHEA, usually 50 mg a day, raised testosterone and acne more reliably than wellbeing or libido. The clearest result is the FDA-approved vaginal insert, Intrarosa.

Every number checked at its primary source · · 20 sources · How we research

Evidence: Randomized trials in women, most small (24 to 93 women) and short, two FDA-reviewed trials of the vaginal insert (255 and 558 women), and meta-analyses of moderate to low certainty.

Silver-haired woman in a red wrap top dances barefoot in a bright living room

Which women were in the DHEA studies?

DHEA (dehydroepiandrosterone) is an adrenal hormone that the body turns into testosterone and estrogens. It is sold to men as a testosterone booster, yet women have carried much of its research. In the largest long trial, at the Mayo Clinic, 57 of the 144 older adults were women1. In the year-long French DHEAge study, 140 of 280 were4. The pooled reviews count women only: 1,273 menopausal women in one, about 3,000 women going through IVF in another1519.

The women fall into four groups, and the answer changes with the group. Older women were given DHEA to replace a level that falls with age. Women with adrenal insufficiency, whose adrenal glands make almost none, were given it to replace what is missing. Women who respond poorly to IVF stimulation were given it to get more from their ovaries. And postmenopausal women with pain at sex got it as a vaginal insert12.

DHEA is in PepVault's library. Add it to a protocol as an oral supplement, and the app logs each day's capsule so you and your prescriber can see exactly when you started. Log it in PepVault

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

DHEA is in PepVault's library. Add it to a protocol as an oral supplement, and the app logs each day's capsule so you and your prescriber can see exactly when you started.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Who did each DHEA trial enroll, and what did it find?

Here is each trial, one row each: who, how many women, their ages, the dose as the trial gave it, what it measured and what it found. A crossover trial gives each woman both DHEA and placebo, one after the other (pepvault.app/glossary/crossover-trial).

WhoWomenAgesTrial doseMeasuredFound
Older women with low DHEA-S (Mayo Clinic, 2 years)57 (27 DHEA, 30 placebo)60 and over50 mg a day by mouthStrength, fitness, body fat, insulin sensitivity, bone, quality of lifeNo change, except bone density up at the wrist; HDL cholesterol down 5 mg/dL123
Healthy older adults (DHEAge, 1 year)140 of 28060 to 7950 mg a day by mouthHormones, bone, libido, skinBone turnover and most libido measures improved in women over 70; skin hydration and thickness improved4
Postmenopausal women with low libido, not on estrogen93Postmenopausal50 mg a day by mouth, 52 weeksSatisfying sexual events, wellbeing, menopause quality of lifeNo difference from placebo at 26 weeks; more acne and hair growth; lipids, insulin and the womb lining unchanged56
Sedentary postmenopausal women in an exercise program31Average 64.650 mg a day by mouth, 12 weeksBody composition, performance, heart risk markersExercise helped; DHEA added nothing, though testosterone doubled7
Women with adrenal insufficiency (crossover)24Adults50 mg each morning, 4 monthsWellbeing, mood, sexualityWellbeing, depression and anxiety scores and sexual interest improved8
Women with adrenal insufficiency (crossover)28 completed of 3320 to 8050 mg a day, 12 weeksStrength, fitness, body composition, muscle proteinNo change9
Poor responders to IVF33 (17 DHEA, 16 control)18 to 4275 mg a day before and during IVFEmbryos, pregnancy, live birthLive birth 23.1% vs 4.0%1011
Painful sex after menopause (the two Intrarosa trials)255 and 558 (87 and 376 on Intrarosa)40 to 75 and 40 to 80 (averages 58.6 and 59.5)6.5 mg vaginal insert nightly, 12 weeksPain at sex, vaginal cells, pHPain eased more than on placebo in both1214

Doses are what each trial gave, told as that, not a dose for anyone. The 33-woman IVF trial was small, and its live-birth difference sat right at the line of chance (P = 0.05)10.

Read down the found column and a pattern shows. Where women already had normal adrenal glands, oral DHEA raised their hormones without moving how they felt or performed. The effects came where something was missing, in adrenal insufficiency, or where the hormone was put straight on the tissue that needed it.

Who did the pooled reviews count?

A meta-analysis pools many trials into one estimate (pepvault.app/glossary/meta-analysis). Each group of women has had one, and each counted a different kind of woman.

GroupReviewTrials and womenWho they wereBottom line
Peri- and postmenopausal womenCochrane, 201528 trials, 1,273 womenAged 36 to 80, over 95% postmenopausal; DHEA by mouth in over 80% of trials, 10 to 1,600 mg a dayNo gain in quality of life; sexual function slightly better; more acne1516
Postmenopausal women, normal adrenalsMayo Clinic review, 201423 trials, 1,188 womenPostmenopausal, adrenal glands working; systemic DHEA, not the vaginal insertNo significant gain in libido, lipids, glucose, weight or bone17
Women with adrenal insufficiencyMeta-analysis, 200910 trialsPrimary or secondary adrenal insufficiencyQuality of life and depression a little better, "perhaps trivial"18
Women going through IVFCochrane, 202428 trials of DHEA or testosterone, 3,002 womenPoor responders in all but three trialsDHEA: little to no change in live births19

The effect sizes, odds ratios and the trials in men are in DHEA benefits: what the studies show (pepvault.app/guides/dhea-what-studies-show). What this table adds is the spread: the menopause reviews are almost all women past menopause, and the IVF review is almost all women whose ovaries respond poorly.

Does DHEA help libido in women?

By mouth, mostly not; as a vaginal insert, a small gain. When the Cochrane reviewers split the sexual-function trials by route, five oral trials in 340 women gave a standardized mean difference of 0.11, which was not significant, while one intravaginal trial in 218 women gave 0.4215. The reviewers’ test did not find the two routes significantly different (P = 0.18), so the split is a lead, not a settled result. That measure puts different questionnaires on one scale: 0.2 is small and 0.5 moderate.

The single trials agree. In 93 postmenopausal women recruited for low desire, 50 mg a day did no better than placebo5. The exceptions were women over 70 in the DHEAge study and women with adrenal insufficiency, whose own levels are lowest48. For the wider picture of low desire and its approved treatments, see pepvault.app/conditions/sexual-dysfunction and pepvault.app/peptides/for/libido.

Commonly reported: little felt day to day on oral DHEA, oilier skin and breakouts within weeks, and for some women more facial or body hair; on the vaginal insert, less dryness and some discharge as it melts.

Who did the DHEA studies leave out?

Knowing who was missing matters as much as who was in. Across the trials above:

  • Women on estrogen. The Mayo trial excluded estrogen replacement, and the low-libido trial enrolled women not using it35. How DHEA adds to hormone therapy was barely tested; the Cochrane review found too little data to compare the two15.
  • Women with a history of breast cancer. Intrarosa was not studied in them, and its label flags this because estrogen is one of the hormones DHEA becomes12.
  • Pregnant and breastfeeding women. Intrarosa is for use after menopause only, and its label has no data in pregnancy12.
  • Women in their 20s and 30s outside IVF. Apart from the IVF trials (18 to 42) and the adrenal trials, the women were postmenopausal: more than 95% in the Cochrane review1116.
  • Women who are not White. In the four placebo-controlled Intrarosa trials, 91% of women were White and 7% Black; the Mayo exercise trial enrolled only Caucasian women712.

What does DHEA do to a woman's hormones and skin?

In women, oral DHEA is a testosterone source. In the exercise trial, 50 mg a day raised DHEA-S, the form a lab measures, by 650% and total testosterone by 100%7. In adrenal insufficiency, it brought testosterone back into the normal range and lowered HDL cholesterol, the protective kind8. That testosterone is why acne and unwanted hair are its side effects in women, nearly four times as likely as on placebo in the pooled trials15.

The vaginal insert stays local by design, and its trials record a different side effect: discharge as the insert melts, in 5.7% of women against 3.7% on placebo over 12 weeks12. The Panjari trial, a year of 50 mg by mouth, found no change in lipids, insulin resistance or the womb lining6, and the two-year Mayo trial reported no major adverse effects1.

PepVault's side-effect log takes acne, hair growth or any symptom you name, dated and rated, so a pattern after starting DHEA is on record rather than remembered. Log it in PepVault

Who decides whether DHEA fits a woman?

Her prescriber. The vaginal insert is a prescription drug for pain at sex after menopause13. Oral DHEA is sold in the US as a supplement, which the FDA does not approve before sale. In its 2014 guideline, the Endocrine Society, with four other societies, recommended against routine DHEA in women with normal adrenal glands or with adrenal insufficiency, citing limited data on effectiveness and safety20.

A DHEA-S blood test shows whether a woman's level is low to begin with, which is who most of the trials enrolled. The library page, pepvault.app/peptides/dhea, has its timeline, side effects and legal status.

PepVault's bloodwork section tracks DHEA-S, total and free testosterone, SHBG and estradiol over time, so each new result sits beside the last one and the day DHEA started. Log it in PepVault

Track it in the app

Sources

  1. Nair KS et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med. 2006. PubMed 17050889
  2. Srinivasan M et al. Effects on lipoprotein particles of long-term dehydroepiandrosterone in elderly men and women and testosterone in elderly men. J Clin Endocrinol Metab. 2010. PubMed 20139233
  3. ClinicalTrials.gov. DHEA and Testosterone Replacement in Elderly (NCT00254371), Mayo Clinic. clinicaltrials.gov
  4. Baulieu EE et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci U S A. 2000. PubMed 10760294
  5. Panjari M et al. A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libido. J Sex Med. 2009. PubMed 19619146
  6. Panjari M et al. The safety of 52 weeks of oral DHEA therapy for postmenopausal women. Maturitas. 2009. PubMed 19410392
  7. Igwebuike A et al. Lack of dehydroepiandrosterone effect on a combined endurance and resistance exercise program in postmenopausal women. J Clin Endocrinol Metab. 2008. PubMed 18029465
  8. Arlt W et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med. 1999. PubMed 10502590
  9. Dhatariya KK et al. Dehydroepiandrosterone replacement therapy in hypoadrenal women: protein anabolism and skeletal muscle function. Mayo Clin Proc. 2008. PubMed 18990320
  10. Wiser A et al. Addition of dehydroepiandrosterone (DHEA) for poor-responder patients before and during IVF treatment improves the pregnancy rate: a randomized prospective study. Hum Reprod. 2010. PubMed 20729538
  11. ClinicalTrials.gov. Dehydroepiandrosterone Supplementation for Poor Responder Patients During in Vitro Fertilization Treatment (NCT01145144), Meir Medical Center. clinicaltrials.gov
  12. Intrarosa (prasterone) vaginal insert, prescribing information. DailyMed, version 9, published August 3, 2026. dailymed.nlm.nih.gov
  13. Drugs@FDA. Intrarosa, NDA 208470: original approval November 16, 2016. accessdata.fda.gov
  14. Labrie F et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause. 2016. PubMed 26731686
  15. Scheffers CS et al. Dehydroepiandrosterone for women in the peri- or postmenopausal phase. Cochrane Database Syst Rev. 2015. PubMed 25879093
  16. Cochrane. Plain language summary: Dehydroepiandrosterone for women in the peri- or postmenopausal phase (CD011066). cochrane.org
  17. Elraiyah T et al. The benefits and harms of systemic dehydroepiandrosterone (DHEA) in postmenopausal women with normal adrenal function: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2014. PubMed 25279571
  18. Alkatib AA et al. A systematic review and meta-analysis of randomized placebo-controlled trials of DHEA treatment effects on quality of life in women with adrenal insufficiency. J Clin Endocrinol Metab. 2009. PubMed 19773400
  19. Naik S et al. Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction. Cochrane Database Syst Rev. 2024. PubMed 38837771
  20. Wierman ME et al. Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014. PubMed 25279570

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo